Summary & Overview
HCPCS Q9968: Visualization Adjunct Injection, 1 mg
HCPCS Level II code Q9968 denotes a 1 mg unit of a non-radioactive, non-contrast visualization adjunct injection (for example, methylene blue or isosulfan blue) used to enhance intraoperative or procedural visualization. Nationally, this code matters because these adjuncts support accurate localization of lymphatics and tissue planes, which can affect procedure time, diagnostic accuracy, and downstream resource use. The code is relevant across surgical and interventional specialties that perform sentinel node mapping, tissue delineation, or targeted staining.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and common use cases, payer coverage considerations, and coding relationships. The publication summarizes typical sites of service and service type, highlights common modifiers and billing practices where available, and notes where input data is absent. This resource is intended to inform billing staff, revenue managers, and policy analysts about the clinical role and coding identity of Q9968, and to provide a reference for benchmarking and payer discussions at the national level.
Billing Code Overview
HCPCS Level II code Q9968 describes an injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg. This item is used as a surgical or procedural adjunct to visually delineate structures such as lymphatics or tissue planes during operative or diagnostic procedures.
Service type: Procedural adjunct drug/biologic administered via injection to assist visualization during procedures.
Typical site of service: Operating room, ambulatory surgical center, interventional radiology suite, or other procedural settings where intraoperative visualization is required.
Clinical & Coding Specifications
Clinical Context
A patient scheduled for sentinel lymph node mapping or intraoperative tissue localization during a surgical oncology or general surgery procedure receives an injection of a visualization adjunct such as methylene blue or isosulfan blue. Typical patients include adults undergoing breast cancer lumpectomy or biopsy with sentinel node mapping, melanoma wide local excision with lymphatic mapping, or gynecologic oncology cases requiring sentinel node identification. The injection is typically administered by the operating surgeon or an interventional radiologist in the operating room or procedure suite shortly before or at the start of the operative procedure. The visualization adjunct is injected intradermally, subdermally, or peritumorally in small volumes (measured by milligrams), and the surgical team observes lymphatic uptake or tissue staining to guide targeted dissection. The medication is supplied in a non-radioactive, non-contrast form and billed per milligram using Q9968. Documentation includes indication, site and route of injection, dose in mg, lot number, timed relation to the operative dissection, and any adverse reaction. Typical site of service: operating room, ambulatory surgery center, or procedure suite. Service type: intraoperative injectable visualization adjunct for tissue or lymphatic mapping.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct procedural service | Use when the injection is a separate, distinct service from other nearby procedures not normally reported together (e.g., separate injection for sentinel node mapping distinct from primary procedure). |